Literature DB >> 30585544

Colorectal Cancer: Causes and Evidence of Chemopreventive Treatments.

Emmanuel Pérez-Escalante1, Raquel Cariño-Cortés2, Eduardo Fernández-Martínez2, Mario I Ortiz2, Víctor Manuel Muñoz-Pérez2, Isabel Sánchez-Crisóstomo2, Luis Jiménez-Ángeles3.   

Abstract

BACKGROUND: Colorectal cancer (CRC) is the second and third most frequent cancer in women and men, respectively; indeed, CRC is placed as the fourth world's most deadly cancer (after lung, liver, and stomach cancer). The incidence of CRC is strongly influenced by nutrition and the high fat/high carbohydrate Western-style diet. CRC is one of the most intensively studied cancer types, partly because of its high prevalence, but also because of the existence of its precursor lesions, tubular or villous adenomas, and more recently serrated adenomas. The morphological steps in the adenomacarcinoma sequence have been elucidated at a molecular level, which allow the identification of the genes responsible for CRC. Review and Conclusions: The main aim of this review is to provide data regarding the pathophysiological characteristics, molecular mechanisms as well as carcinogenic and chemopreventive agents for CRC, with emphasis on evidence supporting their efficacy. These compounds may modulate multiple signaling pathways involved in cell proliferation and apoptosis in transformed cells, they also enhance the host immune system and favor an effective treatment. Despite promising results from experimental studies, only a limited number of these compounds have been tested in clinical trials. The mechanistic spectrum and specificity of the action of phytochemicals represent a complex and evolving field of research. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Colorectal cancer; carcinogenic compounds; chemoprevention; microbiota; molecular mechanisms; natural compounds.

Mesh:

Substances:

Year:  2018        PMID: 30585544     DOI: 10.2174/1389201020666181226112712

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  7 in total

1.  PNMA5 accelerated cellular proliferation, invasion and migration in colorectal cancer.

Authors:  Jie Lin; Xiaokang Zhang; Fan Meng; Fanlin Zeng; Weiyou Liu; Xin He
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

2.  High-fat diet feeding and palmitic acid increase CRC growth in β2AR-dependent manner.

Authors:  Sarwat Fatima; Xianjing Hu; Chunhua Huang; Weixiong Zhang; Jing Cai; Min Huang; Rui-Hong Gong; Minting Chen; Alan H M Ho; Tao Su; Hoi Leong Xavier Wong; Zhaoxiang Bian; Hiu Yee Kwan
Journal:  Cell Death Dis       Date:  2019-09-26       Impact factor: 8.469

3.  TMT-Based Quantitative Proteomics Analysis Reveals the Panoramic Pharmacological Molecular Mechanism of β-Elemonic Acid Inhibition of Colorectal Cancer.

Authors:  Yong Xia; Jinfan Yang; Chao Li; Xiaopeng Hao; Huixia Fan; Yuyang Zhao; Jinfu Tang; Xiufu Wan; Sen Lian; Jian Yang
Journal:  Front Pharmacol       Date:  2022-02-15       Impact factor: 5.810

4.  The interferon regulatory factor 6 promotes cisplatin sensitivity in colorectal cancer.

Authors:  Lin Tan; Weiming Qu; Dajun Wu; Minji Liu; Qiongjia Ai; Hongsai Hu; Qian Wang; Weishun Chen; Hongbing Zhou
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

Review 5.  Revisited Metabolic Control and Reprogramming Cancers by Means of the Warburg Effect in Tumor Cells.

Authors:  Abekura Fukushi; Hee-Do Kim; Yu-Chan Chang; Cheorl-Ho Kim
Journal:  Int J Mol Sci       Date:  2022-09-02       Impact factor: 6.208

6.  The impact of hepatic steatosis on outcomes of colorectal cancer patients with liver metastases: A systematic review and meta-analysis.

Authors:  Shengjie Yang; Renze Peng; Leiming Zhou
Journal:  Front Med (Lausanne)       Date:  2022-09-08

7.  CXCL-8 in Preoperative Colorectal Cancer Patients: Significance for Diagnosis and Cancer Progression.

Authors:  Sara Pączek; Marta Łukaszewicz-Zając; Mariusz Gryko; Piotr Mroczko; Agnieszka Kulczyńska-Przybik; Barbara Mroczko
Journal:  Int J Mol Sci       Date:  2020-03-17       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.